05.01.2022 20:48:10
|
CDC Recommends Pfizer Booster Shot At 5 Months; Additional Dose For Immunocompromised Children
(RTTNews) - The Centers for Disease Control and Prevention or CDC on Wednesday recommended shortening the interval for when people can receive the booster dose. The interval was shortened from 6 months to 5 months for people who have received the Pfizer-BioNTech vaccine. This means that people can now receive an mRNA booster shot five months after they complete their Pfizer-BioNTech primary series. The booster interval recommendation for people who received the J&J vaccine of 2 months or the Moderna vaccine of 6 months has not changed.
The CDC also added that that moderately or severely immunocompromised children between the age of 5 and 11 years can receive an additional primary dose of vaccine, 28 days after their second shot. At this time, only the Pfizer-BioNTech vaccine is authorized and recommended for children aged 5-11.
Commenting on the decision, CDC Director Rochelle Walensky, said, "As we have done throughout the pandemic, we will continue to update our recommendations to ensure the best possible protection for the American people. Following the FDA's authorizations, today's recommendations ensure people are able to get a boost of protection in the face of Omicron and increasing cases across the country, and ensure that the most vulnerable children can get an additional dose to optimize protection against COVID-19. If you or your children are eligible for a third dose or a booster, please go out and get one as soon as you can. Additionally, FDA took action this week to authorize boosters for 12-15 year old - and I look forward to ACIP meeting on Wednesday to discuss this issue."
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
04.02.25 |
Pfizer CEO ‘disappointed’ by Kennedy’s refusal to rebut claims on jab risks (Financial Times) | |
04.02.25 |
AKTIEN IM FOKUS: Ausblick bringt Merck & Co unter Druck - Pfizer auch im Minus (dpa-AFX) | |
04.02.25 |
ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar (dpa-AFX) | |
04.02.25 |
Pfizer vermeldet Umsatzsprung - Aktie dennoch schwächer (dpa-AFX) | |
04.02.25 |
S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte ein Pfizer-Investment von vor 5 Jahren eingebracht (finanzen.at) | |
04.02.25 |
Ausblick: Pfizer stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
28.01.25 |
S&P 500-Wert Pfizer-Aktie: So viel Verlust hätte eine Investition in Pfizer von vor 3 Jahren bedeutet (finanzen.at) | |
21.01.25 |
S&P 500-Papier Pfizer-Aktie: So viel hätten Anleger mit einem Investment in Pfizer von vor einem Jahr verloren (finanzen.at) |
Analysen zu Pfizer Inc.mehr Analysen
05.02.25 | Pfizer Kaufen | DZ BANK | |
05.02.25 | Pfizer Buy | Goldman Sachs Group Inc. | |
05.02.25 | Pfizer Neutral | UBS AG | |
05.02.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
04.02.25 | Pfizer Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Pfizer Inc. | 24,50 | -0,49% |
|